Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

rabies vaccine (Rx)Brand and Other Names:HDCV, Imovax, more...rabies vaccine human diploid cell culture

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

lyophilized powder for reconstitution

  • 2.5 International Unit/1mL
more...

Pre-exposure

Primary

  • 1 mL IM (deltoid region) 3x
  • one injection on each of days 0, 7, and 21 or 28

Booster

  • 1 mL IM (deltoid region) to maintain a serum titer >1:5 serum dilution by RFFIT
  • Test serum for rabies antibodies q6month

Post-exposure

CDC recommendations: 1 mL IM (in deltoid region) x4

One injection each on days 0, 3, 7, and 14 in conjunction with administration of human rabies immune globulin (HRIG) on day 0

HRIG: 20 IU/kg; if anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered IM at an anatomical site distant from vaccine administration

Immunosuppressed patients: Administer 1 mL IM x5 doses on days 0, 3, 7, 14, and 28 with HRIG

Postexposure (Previously Immunized)

1 mL IM (deltoid region) x2

One injection each on days 0 and 3

Administration

Using the longer of the 2 needles supplied, transfer the entire contents of diluent vial into vaccine vial

Mix gently to avoid foaming

The white, freeze-dried vaccine dissolves to give a clear or slightly opaque suspension

Withdraw total amount of dissolved vaccine into the syringe and replace long needle with smaller needle for IM injection

Additional Information

Up-to-date vaccination schedules available at www.cdc.gov/nip/publications

Dosage Forms & Strengths

lyophilized powder for reconstitution

  • 2.5 International Unit/1mL
more...

Pre-exposure

1 mL IM (deltoid region, in small children and infants anterolateral region of thigh) 3x, one injection on each of days 0, 7, and 21 or 28

Postexposure

CDC recommendations: 1 mL IM (in deltoid or gluteal muscle, in small children and infants anterolateral region of thigh) on days 0, 3, 7, and 14 postexposure with human rabies immune globulin (HRIG) on day 0

HRIG: 20 IU/kg; if anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered IM at an anatomical site distant from vaccine administration

Immunosuppressed patients: Administer 1 mL IM x5 doses on days 0, 3, 7, 14, and 28 with HRIG

Postexposure (Previously Immunized)

If previously immunized, give 2 doses (1 mL each) on days 0 and 3 postexposure without HRIG

Next

Interactions

Interaction Checker

rabies vaccine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            >10%

            Injection site pain, soreness, swelling, erythema, itching, burning (30-74%)

            N/V (5-40%)

            Abd pain (5-40%)

            Diarrhea (5-40%)

            Headache (5-40%)

            Fatigue (5-40%)

            Localized enlarged lymph nodes sore throat (5-40%)

            Low grade fever (5-40%)

            Chills (5-40%)

            Muscle ache (5-40%)

            Dizziness (5-40%)

            Malaise (5-40%)

            Postmarketing Reports

            Guillain-Barre synd (rare)

            Anaphylaxis (rare )

            Encephalitis (very rare )

            Meningitis (very rare )

            Retrobulbar neuritis

            Previous
            Next

            Warnings

            Contraindications

            Documented hypersensitivity to neomycin

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: if exposure to rabies suspected, nursing a baby is not a priority as far as immunization is concerned

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Onset (antibodies): 7-10 d

            Duration (antibodies): >1 yr

            Peak Plasma Time (antibodies): 30-60 d

            These products convey active immunity via stimulation of production of endogenously produced antibodies

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Mechanism of Action

            Inactivated virus stimulates active immunity to rabies

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.